Quick Answer
4D Molecular Therapeutics, Inc. reported Total Assets of $566.71 million for the year ending 2025.
- 4D Molecular Therapeutics, Inc. showed an increase of +1.1% in Total Assets from 2024 to 2025.
- This data is from 4D Molecular Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 18, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2021: $270.11 million | Q2 2021: $254.93 million | Q3 2021: $240.62 million | Q1 2022: $324.93 million | Q2 2022: $302.94 million | Q3 2022: $280.16 million | Q1 2023: $244.02 million | Q2 2023: $352.50 million | Q3 2023: $361.61 million | Q1 2024: $629.88 million | Q2 2024: $620.12 million | Q3 2024: $604.03 million | Q1 2025: $515.73 million | Q2 2025: $473.64 million | Q3 2025: $423.98 million.
- Over the full 7 years of available data (2019 to 2025), 4D Molecular Therapeutics, Inc.'s Total Assets has grown by 873.2%.
- Historical annual values: Fiscal year 2025: $566.71 million | Fiscal year 2024: $560.38 million | Fiscal year 2023: $339.89 million | Fiscal year 2022: $261.85 million | Fiscal year 2021: $353.49 million | Fiscal year 2020: $288.33 million | Fiscal year 2019: $58.23 million.
- Data sourced from SEC EDGAR public filings as of August 4, 2026.
Last verified: